Characteristics | Value | Â | Total number of available observations |
---|---|---|---|
Age (years) | Â | Â | 175 |
 Mean ± SDa | 69 ± 8.8 |  |  |
 Median (range) | 70 (46–88) |  |  |
Neoadjuvant treatment | 13 | 9.5% | 137 |
Primary treatment | Â | Â | 137 |
 Radical prostatectomy | 107 | 78% |  |
 EBRTb | 12 | 8.8% |  |
 Androgen deprivation therapy | 10 | 7.3% |  |
 Brachytherapy | 7 | 5.1% |  |
 High Intensity Focused Ultrasound | 1 | 0.7% |  |
Adjuvant external beam radiation therapy | 30 | 22% | 137 |
Prior androgen deprivation therapy | 83 | 61% | 137 |
Ongoing androgen deprivation therapy | 42 | 24% | 175 |
Salvage therapy | Â | Â | 137 |
 No salvage surgery or EBRT | 76 | 55% |  |
 Salvage surgery | 13 | 9.5% |  |
 EBRT | 39 | 28% |  |
 Salvage surgery and EBRT | 9 | 6.6% |  |
Pathologic primary tumour staging | Â | Â | 107 |
 pT2 | 44 | 41% |  |
 pT3 | 60 | 56% |  |
 pT4 | 3 | 2.8% |  |
Pathologic regional lymph node staging | Â | Â | 79 |
 pN0 | 57 | 72% |  |
 pN1 | 22 | 28% |  |
Positive surgical margin at radical prostatectomy | 41 | 41% | 101 |
Number of positive lymph nodes removed at primary treatment | Â | Â | 78 |
 Median (range) | 0 (0–18) |  |  |
Gleason score | Â | Â | 136 |
 5 | 1 | 0.7% |  |
 6 | 9 | 6.6% |  |
 7 | 67 | 49% |  |
 8 | 33 | 24% |  |
 9 | 26 | 19% |  |
PSA value after radical prostatectomy (ng/ml) | Â | Â | 102 |
 Mean ± SD | 0.4 ± 1.6 |  |  |
 Median (range) | 0.04 (0–12) |  |  |
PSA value at PET scan (ng/ml) | Â | Â | 175 |
 Mean ± SD | 11.1 ± 47.5 |  |  |
 Median (range) | 1.6 (0.07–429) |  |  |
PSA doubling time (months) | Â | Â | 171 |
 Mean ± SD | 9.5 ± 10.1 |  |  |
 Median (range) | 6.7 (0.8–96.9) |  |  |
PSA velocity (ng/ml/month) | Â | Â | 171 |
 Mean ± SD | 1.6 ± 9.8 |  |  |
 Median (range) | 0.1 (0–114.5) |  |  |